ArticleDiscover oncology2026
A transcriptomic-based model associated with PARP inhibitor sensitivity and immunogenic signatures in ovarian cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPoly (ADP-ribose) polymerase inhibitors (PARPi) have emerged as a major therapeutic advance in ovarian cancer, particularly for patients with BRCA mutations or homologous recombination deficiency (HRD). However, a significant subset of BRCA wild-type patients also benefit from PARPi therapy, suggesting alternative mechanisms of action, including immune modulation, may be involved. Currently, no robust transcriptomic predictor exists to stratify such patients.
methodsWe developed a transcriptomic predictive model, termed the PARPi-sensor, using RNA-seq data from a patient-derived xenograft (PDX) model treated with niraparib. PARPi-responsive genes (PRGs) were identified and intersected with ovarian cancer–specific differentially expressed genes (DEGs) from TCGA and GTEx. Non-negative matrix factorization (NMF) was applied to define PARPi-responsive patterns (PRPs). A 23-gene PARPi-associated transcriptomic signature was constructed through Cox and LASSO regression analyses.es and validated in TCGA and ICGC cohorts.
resultsThe PARPi-sensor model effectively stratified patients into high- and low-risk subgroups, with the low-risk group exhibiting significantly better overall survival in both cohorts. Functional enrichment revealed that low-risk patients showed upregulation of immune-related pathways, including antigen presentation and B/T cell activation. Immune subtype analysis, immune checkpoint gene expression, and deconvolution using TCIA data indicated that the low-risk group displayed enhanced immune activation and greater inferred responsiveness to immune checkpoint inhibitors. These findings suggest that PARPi may exert immunostimulatory effects, particularly in low-risk patients, independent of BRCA status.
conclusionWe developed and validated a clinically applicable transcriptomic model for identifying transcriptomic features associated with PARPi sensitivity in ovarian cancer. The PARPi-sensor model offers a potential strategy for expanding the use of PARPi to BRCA-wild-type patients and reveals immunological features that may guide combination therapies with immune checkpoint inhibitors. Future research should focus on experimental validation of the proposed mechanisms and prospective clinical application of the model.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.